

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

## Zetia (ezetimibe)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Zetia (ezetimibe)	May be subject to quantity limit

### APPROVAL CRITERIA

Requests for Zetia (ezetimibe) may be when following criteria are met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of one preferred high intensity statin, or two statins at the maximally tolerated dose, and did NOT achieve LDL cholesterol goal (AHA/ACC 2018);

Preferred high intensity statin: atorvastatin (generic Lipitor) 40mg, atorvastatin (generic Lipitor) 80mg

#### **OR**

- II. Individual is statin intolerant based on one of the following:
  - A. Inability to tolerate at least 2 statins, with at least one started at the lowest starting daily dose, demonstrated by intolerable symptoms or clinically significant biomarker changes (NLA 2014); **OR**
  - B. Statin associated rhabdomyolysis after a trial of one statin; **OR**
  - C. Individual has a contraindication<sup>^</sup> for statin therapy including active liver disease, unexplained persistent elevation of hepatic transaminases, or pregnancy;

#### **OR**

- III. Individual has homozygous familial sitosterolemia.

<sup>^</sup>Muscle aches are not considered a contraindication to statin therapy.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

**Key References:**

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 11, 2019.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Grundy SM, Stone NJ, Bailey AL, et. al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. *J Am Coll Cardiol*. 2018. <https://doi.org/10.1016/j.jacc.2018.11.003>.
4. Guyton JR, Bays HE, Grundy SM, Jacobson TA. The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. *J Clin Lipidol*. 2014;8(3 Suppl):S72–81.
5. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. *Endocr Pract*. 2017;23(Suppl 2):1-87.
6. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.